Treatment of central precocious puberty by subcutaneous injections of leuprorelin 3-month depot (11.25 mg)

Journal of Clinical Endocrinology and Metabolism

Volumn 87, Issue 9, 2002, Pages 4111-4116

  Carel, Jean Claude ^a,b,c   Lahlou, Najiba ^a,b,c   Jaramillo, Orlando ^a,b,c   Montauban, Vincent ^a,b,c   Teinturier, Cécile ^a,b,c   Colle, Michel ^a,b,c   Lucas, Christel ^a,b,c   Chaussain, Jean Louis ^a,b,c  

^a Institut National de la Santé et de la Recherche Médicale U342 ^*  (France)

^b Takeda Laboratories   (France)

^c Centre d'Endocrinologie Pediatrique   (France)

Author keywords

[No Author keywords available]

Indexed keywords

GONADORELIN AGONIST; LEUPRORELIN; LUTEINIZING HORMONE; TESTOSTERONE;

ARTICLE; BONE AGE; BONE MATURATION; BREAST DEVELOPMENT; CLINICAL ARTICLE; CLINICAL FEATURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG FORMULATION; FEMALE; GROWTH RATE; HORMONAL REGULATION; HORMONE BLOOD LEVEL; HORMONE DETERMINATION; HUMAN; INHIBITION KINETICS; INJECTION SITE; MALE; PRECOCIOUS PUBERTY; PRIORITY JOURNAL; PUBERTY; SCHOOL CHILD; TESTOSTERONE BLOOD LEVEL; TREATMENT OUTCOME;

CHILD; DELAYED-ACTION PREPARATIONS; ESTRADIOL; FEMALE; FOLLICLE STIMULATING HORMONE; GONADOTROPIN-RELEASING HORMONE; HUMANS; INJECTIONS, SUBCUTANEOUS; LEUPROLIDE; LUTEINIZING HORMONE; MALE; PUBERTY, PRECOCIOUS; TESTOSTERONE; TIME FACTORS;

EID: 18544373719     PISSN: 0021972X     EISSN: None     Source Type: Journal    
DOI: 10.1210/jc.2001-020243     Document Type: Article

References (41)

1. Kaplan SL, Grumbach MM 1990 Clinical review 14: pathophysiology and treatment of sexual precocity. J Clin Endocrinol Metab 71:785-789
2. Mansfield MJ, Beardsworth DE, Loughlin JS, Crawford JD, Bode HH, Rivier J, Vale W, Kushner DC, Crigler Jr JF, Crowley Jr WF 1983 Long-term treatment of central precocious puberty with a long-acting analogue of luteinizing hormone-releasing hormone. N Engl J Med 309:1286-1290
3. Bourguignon JP, Van Vliet G, Vandeweghe M, Malvaux P, Vanderschueren-Lodeweyckx M, Craen M, Du Caju MV, Ernould C 1987 Treatment of central precocious puberty with an intranasal analogue of GnRH (Buserelin). Eur J Pediatr 146:555-560
4. 6-luteinizing hormone-releasing hormone microcapsules. J Clin Endocrinol Metab 62:670-677
5. Kappy MS, Stuart TE, Perelman AH, Clemons RD 1989 Suppression of gonadotropin secretion by a long-acting gonadotropin-releasing hormone analog (leuprolide acetate, Lupron depot) in children with precocious puberty. J Clin Endocrinol Metab 69:1087-1089
6. Tanaka T, Hibi I, Kato K, Saito S, Shimizu N, Suwa S, Nakajima H 1991 A dose finding study of a super long-acting luteinizing hormone-releasing hormone analog (Leuprolide acetate depot, TAP-144-SR) in the treatment of central precocious puberty. Endocrinol Jpn 38:369-376
7. Carel JC, Lahlou N, Guazzarotti L, Joubert-Collin M, Roger M, Colle M, Chaussain JL 1995 Treatment of central precocious puberty with depot leuprolide acetate. Eur J Endocrinol 132:699-704
8. Parker KL, Lee PA 1989 Depot leuprolide acetate for treatment of precocious puberty. J Clin Endocrinol Metab 69:689-691
9. Parker KL, Baens-Bailon RG, Lee PA 1991 Depot leuprolide acetate dosage for sexual precocity. J Clin Endocrinol Metab 73:50-52
10. Neely EK, Hintz RL, Parker B, Bachrach LK, Cohen P, Olney R, Wilson DM 1992 Two-year results of treatment with depot leuprolide acetate for central precocious puberty. J Pediatr 121:634-640
11. DiMartino-Nardi J, Wu R, Varner R, Wong WLT, Saenger P 1994 The effect of luteinizing hormone-releasing hormone analog for central precocious puberty on growth hormone (GH) and GH-binding protein. J Clin Endocrinol Metab 78:664-668
12. Lee PA, Page JG 1989 Leuprolide Study Group. Effects of leuprolide in the treatment of central precocious puberty. J Pediatr 114:321-324
13. Carel JC, Roger M, Ispas S, Tondu F, Lahlou N, Blumberg J, Chaussain JL 1999 Final height after long-term treatment with triptorelin slow-release for central precocious puberty: importance of statural growth after interruption of treatment. J Clin Endocrinol Metab 84:1973-1978
14. Heger S, Partsch CJ, Sippell WG 1999 Long-term outcome after depot gonadotropin-releasing hormone agonist treatment of central precocious puberty: final height, body proportions, body composition, bone mineral density, and reproductive function. J Clin Endocrinol Metab 84:4583-4590
15. Klein KO, Barnes KM, Jones JV, Feuillan PP, Cutler Jr GB 2001 Increased final height in precocious puberty after long-term treatment with LHRH agonists: the National Institutes of Health experience. J Clin Endocrinol Metab 86:4711-4716
16. Paul DL, Conte FA, Grumbach MM, Kaplan SL 1995 Long term effect of gonadotropin-releasing hormone agonist therapy in children with true precocious puberty treated at a median age of less than 5 years. J Clin Endocrinol Metab 80:546-551
17. Lebrethon MC, Bourguignon JP 2000 Management of central isosexual precocity: diagnosis, treatment, outcome. Curr Opin Pediatr 12:394-399
18. Okada H 1997 One- and three-month release injectable microspheres of the LH-RH superagonist leuprorelin acetate. Adv Drug Deliv Rev 28:43-70
19. Okada H, Doken Y, Ogawa Y, Toguchi H 1994 Preparation of three-month depot injectable microspheres of leuprorelin acetate using biodegrad able polymers. Pharm Res 11:1143-1147
20. Okada H, Doken Y, Ogawa Y, Toguchi H 1994 Sustained suppression of the pituitary-gondadal axis by leuprorelin three-month depot microspheres in rats and dogs. Pharm Res 11:1199-1203
21. Lee M, Browneller R, Wu Z, Jung A, Ratanawong C, Sharifi R 1997 Therapeutic effects of leuprorelin microspheres in prostate cancer. Adv Drug Deliv Rev 28:121-138
22. Roger M, Lahlou N, Chaussain JL 1996 Gonadotropin-releasing hormone testing in pediatrics. In: Ranke MB, ed. Diagnostics of endocrine function in children and adolescents. Heidelberg: Johann Ambrosius Barth Verlag; 346-369
23. Lahlou N, Roger M, Chaussain JL, Feinstein MC, Sultan C, Toublanc JE, Schally AV, Scholler R 1987 Gonadotropin and α-subunit secretion during long-term pituitary suppression by D-Trp6-luteinizing hormone-releasing hormone microcapsule as treatment of precocious puberty. J Clin Endocrinol Metab 65:946-953
24. Sempé M, Pédron G, Roy P 1979 Auxologie, méthodes et séquences. Paris: Theraplix
25. Greulich WW, Pyle SI 1959 Radiographic atlas of skeletal development of the hand and wrist. Stanford, CA: Stanford University Press
26. SAS Institute Inc. 1990 SAS user's guide statistics. 6th ed. Cary, NC: SAS Institute Inc.
27. Lahlou N, Carel JC, Chaussain JL, Roger M 2000 Pharmacokmetics and pharmacodynamics of GnRH agonists: clinical implications in pediatrics. J Pediatr Endocrinol Metab 13(Suppl 1):723-737
28. Clayton RN 1993 Regulation of gonadotrophin subunit gene expression. Hum Reprod 8(Suppl 2):29-36
29. Lee PA 1993 Treatment of central precocious puberty with depot Lupron. In: Grave GD, Cutler GB, eds. Sexual precocity: etiology, diagnosis and management. New York: Raven Press Ltd.; 139-150
30. Clemons RD, Kappy MS, Stuart TE, Perelman AH, Hoekstra FT 1993 Long-term effectiveness of depot gonadotropin-releasing hormone analogue in the treatment of children with central precocious puberty. Am J Dis Child 147:653-657
31. Filicori M, Flamigni C, Cognigni G, Dellai P, Arnone R, Falbo A, Capelli M 1993 Comparison of the suppressive capacity of different depot gonadotropin-releasing hormone analogs in women. J Clin Endocrinol Metab 77:130-133
32. Lahlou N, Navratil H, Lanson Y, Lardennois B, Joubert-Collin M, Roger M 1993 Pharmacocinétique de la leuproréline retard et freinage gonadotrope chez des patients traités pour cancer de la prostate. La Lettre du Pharmacologue 7:2-7
33. Wechsel HW, Zerbib M, Pagano F, Coptcoat MJ 1996 Randomized open labelled comparative study of the efficacy, safety and tolerability of leuprorelin acetate 1M and 3M depot in patients with advanced prostatic cancer. Eur Urol 30(Suppl 1):7-14
34. Khan MS, O'Brien A 1998 An evaluation of pharmacokinetics and pharmacodynamics of leuprorelin acetate 3M-depot in patients with advanced and metastatic carcinoma of the prostate. Urol Int 60:33-40
35. Zerbib M, Lucas C, Leblanc V 1997 Effectiveness and tolerance of three month sustained release leuprorelin in the treatment of metastatic prostatic cancer (comparative, randomized, multicentric study). Prog Urol 7:246-253
36. Tunn UW, Bargelloni U, Cosciani S, Fiaccavento G, Guazzieri S, Pagano F 1998 Comparison of LH-RH analogue 1-month depot and 3-month depot by their hormone levels and pharmacokinetic profile in patients with advanced prostate cancer. Urol Int 60(Suppl 1):9-16
37. Crosignani PG, De Cecco L, Gastaldi A, Venturini PL, Oldani S, Vegetti W, Semino A, La Commare P, Vercellini P 1996 Leuprolide in a 3-monthly versus a monthly depot formulation for the treatment of symptomatic endometriosis: a pilot study. Hum Reprod 11:2732-2735
38. Boccardo F, Rubagotti A, Amoroso D, Agostara B, Amadori D, Gallo L, Iacobelli S, Massidda B, Mesiti M, Pacini P, Tomao S, Paganuzzi M, Marroni P 1999 Endocrinological and clinical evaluation of two depot formulations of leuprolide acetate in pre- and perimenopausal breast cancer patients. Cancer Chemother Pharmacol 43:461-466
39. Kaplan SL, Paul DL, Grumbach MM 1993 Long-term therapy of children with true precocious puberty with three GnRH agonists administered by different modes. In: Grave GD, Cutler GB, eds. Sexual precocity: etiology, diagnosis and treatment. New York: Raven Press Ltd.; 61-68
40. Manasco PK, Pescovitz OH, Blizzard RM 1993 Local reactions to depot leuprolide therapy for central precocious puberty. J Pediatr 123:334-335
41. Fornara P, Jocham D 1996 Clinical study results of the new formulation leuprorelin acetate three-month depot for the treatment of advanced prostate carcinoma. Urol Int 56(Suppl 1):18-22